跳至主要内容
临床试验/NCT00834301
NCT00834301Unknown2 期

An Open Label Trial to Evaluate the Effects of a Novel Renal Multivitamin on Inflammation and Other Biomarkers in Endstage Renal Disease Patients

Nephrian2 个研究点 分布在 1 个国家目标入组 25 人开始时间: 2009年1月1日最近更新:
适应症

试验速览

阶段
2 期
发起方
入组人数
25
试验地点
2
主要终点
To assess the efficacy and safety of a novel renal multivitamin on markers of bone and mineral metabolism in an ESRD population.

研究概览

简要总结

The purpose of the study is to determine whether an ingestion of a new renal multivitamin supplement can have a beneficial effect on bone and mineral adn inflammation issues related to patients on dialysis.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • End stage renal disease patients on dialysis for at least 90 days deemed to be at low risk by the investigator for being hospitalized or have concurrent infections
  • Serum phosphorous level > 5 mg/dl
  • Stable phosphate binder regimen for 2 week prior to enrollment
  • Stable dose of Vitamin D for 4 weeks prior to enrollment
  • Stable calcimimetic dose for 4 week prior to enrollment

排除标准

  • patients who are pregnant
  • patients who have pre existing thrombocytopenia defined as a platelet count of <100 x 109/L
  • abnormal LFTs
  • baseline CRP > 15 g/dl
  • known sensitivity to any of the active ingredients
  • patients who are currently enrolled in a clinical trial, or who have been in a clinical trial in the last six months
  • are currently taking any immunosuppressive medications

结局指标

主要结局

To assess the efficacy and safety of a novel renal multivitamin on markers of bone and mineral metabolism in an ESRD population.

时间窗: 8 weeks

次要结局

  • To assess the efficacy and safety of a novel renal multivitamin on markers of inflammation in an ESRD population(8 weeks)

研究者

发起方
Nephrian
申办方类型
Industry

研究点 (2)

Loading locations...

相似试验